Transcatheter aortic valve replacement cohort
Baseline patients’ characteristic and post-operative results for the
TAVR cohort are given in Supplementary Table 3. Patients in the
MetS group (n=180) had greater burdens of comorbidities than the no-MetS
group (n=1948).
Notably, there were no differences in terms of RBC transfused and
incidence of post-operative renal failure. Mortality rate did not differ
between MetS and no-MetS group (2.8% vs. 3%, p=0.99). Only overall LOS
was significantly longer in the MetS group (9 (6) days vs. 8 (6) days,
p<0.001) (Figure 1 A/B/C ).